TY - JOUR
T1 - Performance of chromogenic in situ hybridization on testing HER2 status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) HercepTest results
T2 - A study of two institutions using the conventional and new ASCO/CAP scoring criteria
AU - Gong, Yun
AU - Sweet, William
AU - Duh, Yi Jing
AU - Greenfield, Larry
AU - Tarco, Emily
AU - Trivedi, Smita
AU - Symmans, W. Fraser
AU - Isola, Jorma
AU - Sneige, Nour
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/8
Y1 - 2009/8
N2 - This study specifically addressed the performance of chromogenic in situ hybridization (CISH) on HER2 testing in 66 breast carcinomas with chromosome 17 polysomy and 49 carcinomas with an equivocal HercepTest (DakoCytomation, Carpinteria, CA) score by comparing CISH with corresponding FISH results at 2 test sites and evaluating intersite agreement of CISH results. For tumors with chromosome 17 polysomy, when using the manufacturers' criteria, the concordance values between CISH and FISH at site A, site B, and intersite CISH agreement were 95.8%, 95.5%, and 93.5%, respectively; when using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, the values were 100.0%, 100.0%, and 100.0%, respectively. For tumors with an equivocal HercepTest score, when using the manufacturers' criteria, the concordance values between the 2 methods at site A, site B, and intersite CISH agreement were 88.2%, 95.1%, and 91.1%, respectively; when using the ASCO/CAP criteria, the values were 96.7%, 97.3%, and 97.4%, respectively. These results indicate that CISH is reliable for testing these 2 types of tumors, especially when the ASCO/CAP criteria are used.
AB - This study specifically addressed the performance of chromogenic in situ hybridization (CISH) on HER2 testing in 66 breast carcinomas with chromosome 17 polysomy and 49 carcinomas with an equivocal HercepTest (DakoCytomation, Carpinteria, CA) score by comparing CISH with corresponding FISH results at 2 test sites and evaluating intersite agreement of CISH results. For tumors with chromosome 17 polysomy, when using the manufacturers' criteria, the concordance values between CISH and FISH at site A, site B, and intersite CISH agreement were 95.8%, 95.5%, and 93.5%, respectively; when using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, the values were 100.0%, 100.0%, and 100.0%, respectively. For tumors with an equivocal HercepTest score, when using the manufacturers' criteria, the concordance values between the 2 methods at site A, site B, and intersite CISH agreement were 88.2%, 95.1%, and 91.1%, respectively; when using the ASCO/CAP criteria, the values were 96.7%, 97.3%, and 97.4%, respectively. These results indicate that CISH is reliable for testing these 2 types of tumors, especially when the ASCO/CAP criteria are used.
KW - ASCO/CAP
KW - American Society of Clinical Oncology/College of American Pathologists
KW - Breast carcinoma
KW - CISH
KW - Chromogenic in situ hybridization
KW - Chromosome 17 polysomy
KW - Equivocal
KW - FISH
KW - Fluorescence in situ hybridization
KW - HER2
KW - Immunohistochemistry
UR - http://www.scopus.com/inward/record.url?scp=68549089040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68549089040&partnerID=8YFLogxK
U2 - 10.1309/AJCP4M2VUZCLDALN
DO - 10.1309/AJCP4M2VUZCLDALN
M3 - Article
C2 - 19605817
AN - SCOPUS:68549089040
SN - 0002-9173
VL - 132
SP - 228
EP - 236
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 2
ER -